Patent Legislation Conflict As Argentina Repeals Law

8 January 1996

Once again, Argentina is in conflict over its new patent legislation. In December, a vote by Congress, which followed a vote by the Senate in November, repealed recent regulations passed in relation to patent protection for pharmaceuticals (Marketletters passim). This means that pharmaceutical patent protection is deferred in Argentina until the year 2001.

Gerald Mossinghoff, president of the Pharmaceutical Research and Manufacturers of America is urging the Clinton Administration to adopt "a tough position in response to Argentina's failure to protect patents, despite its repeated pledges to do so." He added that patent piracy is worse in Argentina than in any other Latin American country, and Argentine pirate companies are using the country's inadequate legislation to export piracy to other parts of the region.

The Congress is reported by the local press to be "tired of the pressures" being brought to bear by the USA. It is understood that the Congress is preparing itself for another battle and in December was contemplating requesting that the Ambassador to Argentina, James Cheek, be recalled to the USA.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight